Future research will be needed to better characterize the clinical DLB phenotype in MS, and to examine how coexisting Lewy body pathology (i.e., alpha synuclein) may interact with MS to potentially contribute to cognitive and neurologic decline in older PwMS. This evidence concerns the gene SNCA and myeloid sarcoma.